Stockscreener 앱 받기
9.48
2.27%
-0.22
시간 외 거래:
9.44
-0.04
-0.42%
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Cormorant Asset Management, Lp Sells 30,029 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - news.stocktradersdaily.com
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Corbus Pharmaceuticals stock rises after promising obesity drug safety data - Investing.com
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewswire
Corbus to release phase 1a study results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - The Manila Times
Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 - Quiver Quantitative
Corbus Pharmaceuticals (NASDAQ: CRBP) to release Phase 1a CRB-913 obesity data on Dec. 11 - Stock Titan
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains - 富途牛牛
Will Corbus Pharmaceuticals Holdings Inc. stock remain a Wall Street favoriteMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock trades below fair valueInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock attracts wealthy investorsEntry Point & Advanced Technical Signal Analysis - Newser
What risks investors should watch in Corbus Pharmaceuticals Holdings Inc. stock2025 AllTime Highs & Intraday High Probability Alerts - Newser
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top dividend aristocrat candidate2025 Big Picture & Real-Time Volume Surge Alerts - Newser
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock bottoming after sell offStop Loss & Free Weekly Watchlist of Top Performers - Newser
Corbus Pharmaceuticals (CRBP) Stock Analysis Report | Financials & Insights - Benzinga
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Behavioral Patterns of CRBP and Institutional Flows - news.stocktradersdaily.com
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock could be top winnerForecast Cut & AI Driven Stock Movement Reports - Newser
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
What analysts say about Corbus Pharmaceuticals Holdings Inc 3371 stockSector Performance Drivers & Free Trading Psychology Sessions - earlytimes.in
What is B. Riley’s Forecast for CRBP FY2029 Earnings? - Defense World
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
(CRBP) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
How interest rate cuts could boost Corbus Pharmaceuticals Holdings Inc. stockPortfolio Performance Summary & Free Long-Term Investment Growth Plans - newser.com
Cannabis Pharmaceuticals Market | Global Market Analysis Report2035 - Fact.MR
Can Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain margin levelsWeekly Gains Summary & High Return Trade Opportunity Guides - newser.com
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top hedge fund pickEarnings Beat & AI Enhanced Trading Signals - newser.com
Can Corbus Pharmaceuticals Holdings Inc. stock surprise with earnings upside2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
What analyst consensus says on Corbus Pharmaceuticals Holdings Inc. stock2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
0.36%
1.05%
자본화:
|
볼륨(24시간):